Legislation aimed to do away with unfair direct and indirect renumeration (DIR) fees is moving forward.
Many cite PBM fees as the primary cause in NCPA survey.
Eight pharmacy groups lauded a letter urging the Trump administration to reform direct and indirect remuneration (DIR) fees.
DIR abuse might require Presidential and Congressional intervention.
Both pharmacy groups state that rule should have addressed DIR fees.
Reimbursement reform tops list of priorities, from DIR fees to rebates.
More than 150 pharmacy stakeholder organizations — including drug chains such as Walgreens — support a Centers for Medicare and Medicaid Services’ proposal that would eliminate direct and indirect remuneration (DIR) fees.
What the experts have to say about recent shifts in pharmacy law and practice.
NCPA found three things that pharmacists desperately want changed. Here’s how they’re going to do it.
The speech made headlines for what it means for patients, but what exactly will it mean for pharmacy?